209 related articles for article (PubMed ID: 32005813)
1. Understanding the structural basis of HIV-1 restriction by the full length double-domain APOBEC3G.
Yang H; Ito F; Wolfe AD; Li S; Mohammadzadeh N; Love RP; Yan M; Zirkle B; Gaba A; Chelico L; Chen XS
Nat Commun; 2020 Jan; 11(1):632. PubMed ID: 32005813
[TBL] [Abstract][Full Text] [Related]
2. DNA mutagenic activity and capacity for HIV-1 restriction of the cytidine deaminase APOBEC3G depend on whether DNA or RNA binds to tyrosine 315.
Polevoda B; Joseph R; Friedman AE; Bennett RP; Greiner R; De Zoysa T; Stewart RA; Smith HC
J Biol Chem; 2017 May; 292(21):8642-8656. PubMed ID: 28381554
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
4. Crystal Structure of a Soluble APOBEC3G Variant Suggests ssDNA to Bind in a Channel that Extends between the Two Domains.
Maiti A; Myint W; Delviks-Frankenberry KA; Hou S; Kanai T; Balachandran V; Sierra Rodriguez C; Tripathi R; Kurt Yilmaz N; Pathak VK; Schiffer CA; Matsuo H
J Mol Biol; 2020 Nov; 432(23):6042-6060. PubMed ID: 33098858
[TBL] [Abstract][Full Text] [Related]
5. Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA.
Friew YN; Boyko V; Hu WS; Pathak VK
Retrovirology; 2009 Jun; 6():56. PubMed ID: 19497112
[TBL] [Abstract][Full Text] [Related]
6. Crystal structures of APOBEC3G N-domain alone and its complex with DNA.
Xiao X; Li SX; Yang H; Chen XS
Nat Commun; 2016 Aug; 7():12193. PubMed ID: 27480941
[TBL] [Abstract][Full Text] [Related]
7. Dimerization regulates both deaminase-dependent and deaminase-independent HIV-1 restriction by APOBEC3G.
Morse M; Huo R; Feng Y; Rouzina I; Chelico L; Williams MC
Nat Commun; 2017 Sep; 8(1):597. PubMed ID: 28928403
[TBL] [Abstract][Full Text] [Related]
8. Structural Determinants of the APOBEC3G N-Terminal Domain for HIV-1 RNA Association.
Fukuda H; Li S; Sardo L; Smith JL; Yamashita K; Sarca AD; Shirakawa K; Standley DM; Takaori-Kondo A; Izumi T
Front Cell Infect Microbiol; 2019; 9():129. PubMed ID: 31165049
[TBL] [Abstract][Full Text] [Related]
9. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1.
Huthoff H; Autore F; Gallois-Montbrun S; Fraternali F; Malim MH
PLoS Pathog; 2009 Mar; 5(3):e1000330. PubMed ID: 19266078
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of DNA cytidine deaminase ABOBEC3G catalytic deamination domain suggests a binding mode of full-length enzyme to single-stranded DNA.
Lu X; Zhang T; Xu Z; Liu S; Zhao B; Lan W; Wang C; Ding J; Cao C
J Biol Chem; 2015 Feb; 290(7):4010-21. PubMed ID: 25542899
[TBL] [Abstract][Full Text] [Related]
11. Nanoscale Characterization of Interaction of APOBEC3G with RNA.
Pan Y; Sun Z; Maiti A; Kanai T; Matsuo H; Li M; Harris RS; Shlyakhtenko LS; Lyubchenko YL
Biochemistry; 2017 Mar; 56(10):1473-1481. PubMed ID: 28029777
[TBL] [Abstract][Full Text] [Related]
12. Apobec3G-Based Strategies to Defeat HIV Infection.
Ran X; Ao Z; Yao X
Curr HIV Res; 2016; 14(3):217-24. PubMed ID: 26957196
[TBL] [Abstract][Full Text] [Related]
13. Identification of the HIV-1 Vif and Human APOBEC3G Protein Interface.
Letko M; Booiman T; Kootstra N; Simon V; Ooms M
Cell Rep; 2015 Dec; 13(9):1789-99. PubMed ID: 26628364
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Vif inhibits G to A hypermutations catalyzed by virus-encapsidated APOBEC3G to maintain HIV-1 infectivity.
Wang Y; Kinlock BL; Shao Q; Turner TM; Liu B
Retrovirology; 2014 Oct; 11():89. PubMed ID: 25304135
[TBL] [Abstract][Full Text] [Related]
15. Long-term passage of Vif-null HIV-1 in CD4
Miyagi E; Kao S; Fumitaka M; Buckler-White A; Plishka R; Strebel K
Virology; 2017 Apr; 504():1-11. PubMed ID: 28131088
[TBL] [Abstract][Full Text] [Related]
16. Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C.
Wang T; Zhang W; Tian C; Liu B; Yu Y; Ding L; Spearman P; Yu XF
Virology; 2008 Jul; 377(1):71-9. PubMed ID: 18495196
[TBL] [Abstract][Full Text] [Related]
17. Mechanism for APOBEC3G catalytic exclusion of RNA and non-substrate DNA.
Solomon WC; Myint W; Hou S; Kanai T; Tripathi R; Kurt Yilmaz N; Schiffer CA; Matsuo H
Nucleic Acids Res; 2019 Aug; 47(14):7676-7689. PubMed ID: 31424549
[TBL] [Abstract][Full Text] [Related]
18. An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
Bennett RP; Stewart RA; Hogan PA; Ptak RG; Mankowski MK; Hartman TL; Buckheit RW; Snyder BA; Salter JD; Morales GA; Smith HC
Antiviral Res; 2016 Dec; 136():51-59. PubMed ID: 27825797
[TBL] [Abstract][Full Text] [Related]
19. Structural Investigations on the Interactions between Cytidine Deaminase Human APOBEC3G and DNA.
Yan X; Lan W; Wang C; Cao C
Chem Asian J; 2019 Jul; 14(13):2235-2241. PubMed ID: 31116511
[TBL] [Abstract][Full Text] [Related]
20. Structural basis of sequence-specific RNA recognition by the antiviral factor APOBEC3G.
Yang H; Kim K; Li S; Pacheco J; Chen XS
Nat Commun; 2022 Dec; 13(1):7498. PubMed ID: 36470880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
